NovaBay Pharmaceuticals (NBY) 10-Q 6 Aug 20 2020 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2020	Aug. 04, 2020
Document Information [Line Items]
Entity Registrant Name	NOVABAY PHARMACEUTICALS, INC.
Entity Central Index Key	0001389545
Trading Symbol	nby
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		41,739,904
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $0.01 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
ASSETS
Cash and cash equivalents	$ 8,775	$ 6,937
Accounts receivable, net of allowance for doubtful accounts ($0 and $51 at June 30, 2020 and December 31, 2019, respectively)	1,391	1,066
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments ($206 and $247 at June 30, 2020 and December 31, 2019, respectively)	626	492
Prepaid expenses and other current assets	1,116	886
Total current assets	11,908	9,381
Operating lease right-of-use assets	803	1,252
Property and equipment, net	84	110
Other assets	477	477
TOTAL ASSETS	13,272	11,220
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	1,291	331
Accrued liabilities	1,282	1,778
Deferred revenue	115
Operating lease liability	619	930
Notes payable, related party	104	1,202
Deferred income	432	0
Convertible note	418	1,409
Embedded derivative liability	1	3
Warrant liability	39	34
Total current liabilities	4,301	5,687
Operating lease liabilities-non-current	303	505
Warrant liability	7,685	4,055
Total liabilities	12,289	10,247
Stockholders' equity:
Preferred stock: 5,000 shares authorized; none issued and outstanding at June 30, 2020 and December 31, 2019
Common stock, $0.01 par value; 75,000 shares and 50,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; 34,648 and 27,938 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	346	279
Additional paid-in capital	131,725	125,718
Accumulated deficit	(131,088)	(125,024)
Total stockholders' equity	983	973
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 13,272	$ 11,220

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Accounts receivable, allowance for doubtful accounts	$ 0	$ 51
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments	$ 206	$ 247
Preferred stock, shares authorized (in shares)	5,000	5,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000	50,000
Common stock, shares issued (in shares)	34,648	27,938
Common stock, shares outstanding (in shares)	34,648	27,938

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Sales:
Total sales, net	$ 3,984	$ 1,789	$ 5,876	$ 3,280
Product cost of goods sold	2,040	403	2,621	744
Gross profit	1,944	1,386	3,255	2,536
Research and development	115	32	124	117
Sales and marketing	1,423	1,535	2,983	5,066
General and administrative	1,477	1,198	2,754	2,803
Total operating expenses	3,015	2,765	5,861	7,986
Operating loss	(1,071)	(1,379)	(2,606)	(5,450)
Non-cash loss on changes in fair value of warrant liability	(3,772)	(487)	(3,635)	(544)
Non-cash (loss) gain on changes in fair value of embedded derivative liability		(246)	2	(246)
Other income (expense), net	362	(387)	176	(447)
Loss before provision for income taxes	(4,481)	(2,499)	(6,063)	(6,687)
Provision for income taxes	(1)	(2)	(1)	(3)
Net loss and comprehensive loss	$ (4,482)	$ (2,501)	$ (6,064)	$ (6,690)
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.15)	$ (0.14)	$ (0.21)	$ (0.38)
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic and diluted) (in shares)	30,384	18,613	29,012	17,857
Product [Member]
Sales:
Total sales, net	$ 3,979	$ 1,789	$ 5,871	$ 3,239
Product and Service, Other [Member]
Sales:
Total sales, net	$ 5		$ 5	$ 41

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Operating activities:
Net loss	$ (6,064,000)	$ (6,690,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	28,000	33,000
Impairment of operating lease right-of-use assets	0	125,000
Non-cash loss on changes in fair value of warrant liability	3,635,000	544,000
Non-cash (gain) loss on changes in fair value of embedded derivative liability	(2,000)	246,000
Interest expense related to amortization of debt issuance and debt discount	143,000	263,000
Interest expense related to amortization of debt issuance related to related party notes payable	2,000	15,000
Changes in operating assets and liabilities:
Accounts receivable	(498,000)	1,849,000
Inventory	(134,000)	(383,000)
Prepaid expenses and other current assets	(230,000)	80,000
Operating lease right-of-use assets	449,000	458,000
Other assets		9,000
Accounts payable and accrued liabilities	473,000	(1,411,000)
Operating lease liabilities	(513,000)	(519,000)
Deferred revenue	115,000	(41,000)
Related party notes payable	73,000	115,000
Long-term obligations		60,000
Deferred income	432,000
Net cash used in operating activities	(1,906,000)	(5,000,000)
Investing activities:
Purchases of property and equipment		(19,000)
Net cash used in investing activities		(19,000)
Financing activities:
Proceeds from common stock issuances, net	5,220,000	2,467,000
Proceeds from issuance of related party notes payable		1,000,000
Proceeds from exercise of options, net		189,000
Proceeds from stock options & RSUs sold to cover taxes		4,000
Proceeds from exercise of warrants	669,000	46,000
Proceeds from convertible notes, net of discount		2,000,000
Payment on the convertible note	(1,145,000)
Payment on the related party loan	(1,000,000)
Debt issuance cost		(202,000)
Net cash provided by financing activities	3,744,000	5,504,000
Net increase in cash, cash equivalents, and restricted cash	1,838,000	485,000
Cash, cash equivalents and restricted cash, beginning of period	7,412,000	3,658,000
Cash, cash equivalents and restricted cash, end of period	9,250,000	4,143,000
Supplemental disclosure of cash flow information:
Interest paid	55,000
Addition of operating lease, right-of-use asset		2,473,000
Fixed asset purchases, included in accounts payable and accrued liabilities		10,000
Warrant liability transferred to equity		400,000
Non-cash payment of related party loan accrued interest offset by related party accounts receivable – see Note 9	173,000
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	137,000	202,000
Nonemployees [Member] | Share-based Payment Arrangement, Option [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense for options and stock issued	10,000	14,000
Employee [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option modification expense	36,000	21,000
Former Employee [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option modification expense	2,000	10,000
Accounting Standards Update 2014-09 [Member]
Supplemental disclosure of cash flow information:
Cumulative effect of adoption of New ASU		$ 56,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	ATM Program [Member]Common Stock [Member]	ATM Program [Member]Additional Paid-in Capital [Member]	ATM Program [Member]Retained Earnings [Member]	ATM Program [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018					17,089,000
Balance at Dec. 31, 2018					$ 171	$ 119,764	$ (114,981)	$ 4,954
Net loss							(4,189)	(4,189)
Vesting of restricted stock awards (in shares)					6,000
Vesting of restricted stock awards						10		10
Stock-based compensation expense related to employee and director stock options						107		107
Stock-based compensation expense related to non-employee stock options						7		7
Reclassification of Warrant Liability to Equity – see Note 2						412	(356)	56
Debt discount associated with convertible note – beneficial conversion feature						184		184
Balance (in shares) at Mar. 31, 2019					17,095,000
Balance at Mar. 31, 2019					$ 171	120,484	(119,526)	1,129
Balance (in shares) at Dec. 31, 2018					17,089,000
Balance at Dec. 31, 2018					$ 171	119,764	(114,981)	4,954
Net loss								$ (6,690)
Balance (in shares) at Jun. 30, 2019					20,733,000
Issuance of common stock for option exercises (in shares)								83,000
Balance at Jun. 30, 2019					$ 207	123,518	(122,056)	$ 1,669
Balance (in shares) at Mar. 31, 2019					17,095,000
Balance at Mar. 31, 2019					$ 171	120,484	(119,526)	1,129
Net loss							(2,501)	(2,501)
Issuance of common stock in connection with exercise of warrants (in shares)					286,000
Issuance of common stock in connection with exercise of warrants					$ 3	443		446
Stock-based compensation expense related to employee and director stock options						7		7
Stock-based compensation expense related to non-employee stock options						95		95
Issuance of common stock, net of offering costs (in shares)					3,269,000
Issuance of common stock, net of offering costs					$ 33	2,434		2,467
Stock option modification						21		21
Balance (in shares) at Jun. 30, 2019					20,733,000
Down round feature adjustment related to warrants						29	(29)
Issuance of common stock for option exercises (in shares)					83,000			83,000
Issuance of common stock for option exercises						189		$ 189
Debt discount associated with convertible note – beneficial conversion feature						(184)		(184)
Balance at Jun. 30, 2019					$ 207	123,518	(122,056)	1,669
Balance (in shares) at Dec. 31, 2019					27,938,000
Balance at Dec. 31, 2019					$ 279	125,718	(125,024)	973
Net loss							(1,582)	(1,582)
Issuance of common stock in connection with exercise of warrants (in shares)					299,000
Issuance of common stock in connection with exercise of warrants					$ 3	198		201
Vesting of restricted stock awards (in shares)					2,000
Vesting of restricted stock awards						2		2
Stock-based compensation expense related to employee and director stock options						45		45
Stock-based compensation expense related to non-employee stock options						12		12
Balance (in shares) at Mar. 31, 2020					28,239,000
Balance at Mar. 31, 2020					$ 282	125,975	(126,606)	(349)
Balance (in shares) at Dec. 31, 2019					27,938,000
Balance at Dec. 31, 2019					$ 279	125,718	(125,024)	973
Net loss								(6,064)
Balance (in shares) at Jun. 30, 2020					34,648,000
Balance at Jun. 30, 2020					$ 346	131,725	(131,088)	983
Balance (in shares) at Mar. 31, 2020					28,239,000
Balance at Mar. 31, 2020					$ 282	125,975	(126,606)	(349)
Net loss							(4,482)	(4,482)
Issuance of common stock in connection with exercise of warrants (in shares)					571,000
Issuance of common stock in connection with exercise of warrants					$ 6	462		468
Stock-based compensation expense related to employee and director stock options						92		92
Stock-based compensation expense related to non-employee stock options						(2)		(2)
Issuance of common stock, net of offering costs (in shares)	5,838,000			5,836,792
Issuance of common stock, net of offering costs	$ 58	$ 5,162		$ 5,220
Stock option modification						36		36
Balance (in shares) at Jun. 30, 2020					34,648,000
Balance at Jun. 30, 2020					$ 346	$ 131,725	$ (131,088)	$ 983

Note 1 - Organization

Note 1 - Organization	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. NovaBay Pharmaceuticals, Inc. (the “Company”) is a medical device company predominantly focused on eye care. Our main product is Avenova ® second 2020, KN95 “KN95 19 KN95 third The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, April 2016, KN95 Liquidity Based primarily on the funds available at June 30, 2020, June 30, 2021. may may 19

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars. Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three June 30, 2020 December 31, 2019, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets: June 30, December 31, 2020 2019 Cash and cash equivalents $ 8,775 $ 6,937 Restricted cash included in Other assets 475 475 Total cash, cash equivalents, and restricted cash in the statements of cash flows $ 9,250 $ 7,412 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the three six June 30, 2020, 1 KN95 2 three During the three six June 30, 2020 2019, Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 KN95 Masks $ 2,839 $ — $ 3,012 $ — Avenova 1,140 1,580 2,686 3,030 Other products — 209 173 209 Total product revenue, net 3,979 1,789 5,871 3,239 Other revenue, net 5 — 5 41 Total sales, net $ 3,984 $ 1,789 $ 5,876 $ 3,280 The Company does not KN95 During the three six June 30, 2020 2019, 10% Three Months Ended June 30, Six Months Ended June 30, Major distribution or collaboration partner 2020 2019 2020 2019 Avenova Direct via Amazon 12 % * % 21 % * % Avenova distributor A * % 13 % * % 18 % Avenova distributor B * % 12 % * % 15 % Avenova distributor C * % 23 % * % 19 % *Not 10% As of June 30, 2020 December 31, 2019, 10% June 30, December 31, Major distribution or collaboration partner 2020 2019 Customer A from sales of KN95 Masks 52 % — % Avenova Direct via Amazon * % 20 % Avenova distributor A 12 % 28 % Avenova distributor B * % 13 % Avenova distributor C * % 19 % *Not 10% The Company relies on two not third may may not may 19 Fair Value of Financial Assets and Liabilities The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, related party notes payable, a convertible note, and warrants. The fair value of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and related party notes payable is carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Secured Convertible Promissory Note issued on March 26, 2019 ( The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. Management did not June 30, 2020. December 31, 2019, $51 120 Inventory Inventory is comprised of ( 1 2 3 June 30, 2020 December 31, 2019, $206 $247 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. Impairment of Long-Lived Assets and Operating Lease Right-of-Use Assets The Company accounts for long-lived assets and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment may not first 2019, $125 no three six June 30, 2020. Leases In February 2016, No. 2016 02, Leases (Topic 842 January 1, 2019. not At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no Comprehensive Income (Loss) ASC 220 , Comprehensive Income, Revenue Recognition Revenue generated through the Company's webstore for Avenova and KN95 third Revenue generated through Amazon.com for Avenova and other products is recognized upon fulfillment by Amazon.com, which generally occurs upon delivery of the related products to a third The Company also generates Avenova product revenue through product sales to its major distribution partners and a limited number of partner pharmacies. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company does not not 30 one one Bulk orders of KN95 KN95 Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including Emergency Use Authorization (“EUA”) submissions to the Food and Drug Administration (“FDA”). Research and development costs may no Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company's stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these programs is recognized in the Company's condensed consolidated statements of stockholders' equity (deficit) based on their fair values as they are earned under the applicable vesting terms or the length of an offering period. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liability The Company accounts for the issuance of common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging On January 1, 2019, 2017 11, Earnings Per Share (Topic 260 480 815 2017 11, March 31, 2019 $56 $56 $356 January 1, 2019, $356 Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During the three six June 30, 2020 2019, no The following table sets forth the calculation of basic and diluted EPS: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator Net loss $ (4,482 ) $ (2,501 ) $ (6,064 ) $ (6,690 ) Less retained earning reduction related to down round feature triggered — (29 ) — (29 ) Net loss attributable to common stockholders $ (4,482 ) $ (2,530 ) $ (6,064 ) $ (6,719 ) Denominator Weighted average shares of common stock outstanding, basic and diluted 30,384 18,613 29,012 17,857 Net loss per share attributable to common stockholders, basic and diluted $ (0.15 ) $ (0.14 ) $ (0.21 ) $ (0.38 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of June 30, (in thousands) 2020 2019 Period end stock options to purchase common stock 2,692 2,274 Period end common stock warrants 7,105 1,624 9,797 3,898 Shares underlying the Convertible Note were excluded from the EPS calculation as the Company intends to settle the Convertible Note in cash in lieu of stock pursuant to the securities purchase agreement, dated August 8, 2019, “August 12, August Recent Accounting Pronouncements In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13 January 1, 2020 not In June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 January 1, 2023. January 1, 2023. In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 first 2021

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Fair Value Disclosures [Text Block]	NOTE 3. The Company follows ASC 820, Fair Value Measurements and Disclosures The Company's cash equivalents are classified within Level 1 2 1 2 As of June 30, 2020, October 2015 August 2019, 35,107 July 2011 first 2020, $15 3 11, A call option and the put feature within the Convertible Note (as defined below) is recorded as a derivative liability on the Company's condensed consolidated balance sheet with a corresponding debt discount which is netted against the face value of the Convertible Note. The fair value of embedded derivative liability is classified within Level 3 10, The following table presents the Company's assets and liabilities measured at fair value on a recurring basis as of June 30, 2020: Fair Value Measurements Using (in thousands) Balance at June 30, 2020 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Liabilities Warrant liability $ 7,724 $ — $ — $ 7,724 Embedded derivative liability 1 — — 1 Total liabilities $ 7,725 $ — $ — $ 7,725 The following table presents the Company's assets and liabilities measured at fair value on a recurring basis as of December 31, 2019: Fair Value Measurements Using (in thousands) Balance at December 31, 2019 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Liabilities Warrant liability $ 4,089 $ — $ — $ 4,089 Embedded derivative liability 3 — — 3 Total liabilities $ 4,092 $ — $ — $ 4,092 The following is a reconciliation of the beginning and ending balances for the liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3 three six June 30, 2020: (in thousands) Level 3 liabilities Fair value of warrant liability and embedded derivative liability at December 31, 2019 $ 4,092 Decrease in fair value of warrant liability at March 31, 2020 (122 ) Decrease in fair value of embedded derivative liability at March 31, 2020 (2 ) Decrease in fair value related to warrants expired (15 ) Fair value of warrant liability and embedded derivative liability at March 31, 2020 3,953 Increase in fair value of warrant liability at June 30, 2020 3,772 Fair value of warrant liability and embedded derivative liability at June 30, 2020 $ 7,725

Note 4 - Prepaid Expenses and O

Note 4 - Prepaid Expenses and Other Current Assets	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Block]	NOTE 4. Prepaid expenses and other current assets consisted of the following: (in thousands) June 30, December 31, 2020 2019 Prepaid insurance $ 455 $ 94 Prepaid sales rebates 142 401 Receivables from at-the-marketing offering 96 — Related party receivables 79 — Prepaid inventory 73 — Prepaid security deposit for lease 65 65 Prepaid patents 44 85 Prepaid dues and subscription 31 82 Retainer 17 46 Other 114 113 Total prepaid expenses and other current assets $ 1,116 $ 886

Note 5 - Inventory

Note 5 - Inventory	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 5. Inventory consisted of the following: (in thousands) June 30, December 31, 2020 2019 Raw materials and supplies $ 180 $ 185 Finished goods 652 554 Less: Reserve for excess and obsolete inventory (206 ) (247 ) Total inventory, net $ 626 $ 492

Note 6 - Property and Equipment

Note 6 - Property and Equipment	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 6. Property and equipment consisted of the following: (in thousands) June 30, December 31, 2020 2019 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 343 349 Production equipment 65 65 Leasehold improvements 79 79 Total property and equipment, at cost 664 670 Less: accumulated depreciation and amortization (580 ) (560 ) Total property and equipment, net $ 84 $ 110 Depreciation and amortization expense was $14 $16 three June 30, 2020 2019, $28 $33 six June 30, 2020 2019, During the three six June 30, 2020, no three six June 30, 2019.

Note 7 - Accrued Liabilities

Note 7 - Accrued Liabilities	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 7. Accrued liabilities consisted of the following: (in thousands) June 30, December 31, 2020 2019 Avenova contract liabilities $ 478 $ 822 Employee payroll and benefits 237 463 Consulting service 210 109 Sublease security deposit 198 198 Prepaid rent from subleasee 118 — Related party consulting service — 33 Other 41 153 Total accrued liabilities $ 1,282 $ 1,778

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 8. Directors and Officers Indemnification As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may not June 30, 2020. In the normal course of business, the Company provides indemnification of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not June 30, 2020. Legal Matters From time to time, the Company may July 29, 2019, $370,000 not June 30, 2020, no Leases The Company leases office space for its corporate headquarters located in Emeryville, California. The initial lease term is through February 28, 2022. one five 5 October 31, 2020. no not August 4, 2020, July 31, 2020 August 31, 2020 30 In July 2016, September 8, 2016. October 21, 2020 no not August 4, 2020, July 31, 2020, August 31, 2020 On August 4, 2020, August 31, 2020. In addition to the facility leases, the Company previously leased 54 36 first 2017. first 2019, $125 December 31, 2019. fourth 2019, 15 December 31, 2019. first 2020. Additionally, the Company has an operating lease for two October 2022. not In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not not not The components of lease expense for the three six June 30, 2020 2019 Lease Costs Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost $ 250 $ 276 $ 514 $ 588 Sublease income (158 ) (158 ) (316 ) (316 ) Net lease cost $ 92 $ 118 $ 198 $ 272 Other information Operational cash flow used for operating leases $ 284 $ 324 $ 580 $ 648 June 30, 2020 2019 Weighted-average remaining lease term (in years) 1.4 2.0 Weighted-average discount rate 12 % 12 % Future lease payments under non-cancelable leases as of June 30, 2020 Remaining in 2020 $ 461 2021 454 2022 88 Thereafter — Total future minimum lease payments 1,003 Less imputed interest (81 ) Total $ 922 Reported as: Operating lease liability $ 619 Operating lease liability- non-current 303 Total $ 922 Future lease payments to be received under non-cancelable leases as of June 30, 2020 $194 2020. Contracts On May 13, 2020, 2 $0.865 June 30, 2020, not no On April 16, 2020, 2 December 31, 2021. 12% June 30, 2020, not no In connection with the Microprofit Agreement, on April 16, 2020, June 29, 2020.

Note 9 - Related Party Notes Pa

Note 9 - Related Party Notes Payable	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Related Party Notes Payable [Text Block]	NOTE 9. On February 27, 2019, $1.0 June 25, 2019 May 14, 2020 ( $150 $300 65,178 40ml 40,644 first 2020. second May 14, 2020, $1.0 June 30, 2020, $104 24,534 In connection with the Promissory Note, the Company 2% one March 1, 2020. $100 no $20 The interest expense recognized, including amortization of the issuance costs, was $27 $75 three six June 30, 2020, $98 $130 three six June 30, 2019,

Note 10 - Convertible Note

Note 10 - Convertible Note	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 10. On March 26, 2019 ( $2.2 10% September 26, 2020, $2.0 $200 $15 $182 The Convertible Note provides the Lender with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into unregistered shares of the Company's common stock at a conversion price of $1.65 September 26, 2019, $200 may $1.65 85% 20 may 115% The Company has reserved 3,200,000 Pursuant to a Security Agreement between the Company and the Lender, repayment of the Convertible Note is secured by all of the assets of the Company. The Convertible Note contains events of default upon the occurrence and during the continuance of which all obligations may 15%, The Company's prepayment terms represent an embedded call option, the Lender's share redemption terms represent an embedded put option and certain events of default represent embedded derivatives, each of which require bifurcation. A single derivative comprising all bifurcatable features was measured at fair value using a Monte Carlo simulation model. The fair value of the embedded derivative at issuance of the Convertible Note on March 26, 2019 $0.4 March 26, 2019 As of Assumption March 26, 2019 Stock price (latest bid price) $ 1.28 Equity volatility 93.8 % Risk-free interest rate 2.34 % Remaining term 1.5 The Company determined that the fair value of the embedded derivative liability was immaterial as of June 30, 2020. The key assumptions used to value the combined embedded derivative as of December 31, 2019 Assumption As of December 31, 2019 Stock price $ 0.65 Equity volatility 192.6 % Risk-free interest rate 1.60 % Remaining term 0.74 The aggregate $627 $197 June 30, 2020: (in thousands) Principal amount $ 419 Unamortized discount (1 ) Total debt 418 Less: short-term 418 Long-term $ — The discount and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Convertible Note, assuming that the Convertible Note will be redeemed at the maximum $200 September 2019. three six June 30, 2020, 37% 43%, $59 $199 three six June 30, 2020, three six June 30, 2019, 54%. $302 $322 three six June 30, 2019, On August 8, 2019, August 4,198,566 4,198,566 4,198,566 $1.00 August may $2.00. 12, August The Lender has redeemed $200 September 27, 2019. three six June 30, 2020, $600 $1.2 $579 $1.1 June 30, 2020, (in thousands) 2020 $ 419 2021 and thereafter — Total $ 419

Note 11 - Warrant Liability

Note 11 - Warrant Liability	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Other Liabilities Disclosure [Text Block]	NOTE 11. In July 2011, 139,520 $33.25 January 1, 2012 July 5, 2016. 480, Distinguishing Liabilities from Equity 480 $66.50 ten not fifteen one third In October 2015, March 3, 2015 ( “2015 twenty two March 3, 2016). October 2015 15 five 2015 “March 2015 June 29, 2011 ( “July 2011 March 2015 July 2011 $5.00 July 2011 March 6, 2020. July 2011 March 2015 $5.00 $5.00, In October 2015, 492,000 442,802 “October 2015 $5.00 “October 2015 60 October 2015 $5.00 $2.1 In February 2016, July 2011, March 2015 October 2015 $1.81 In May 2019, July 2011 March 2015 October 2015 $0.2061 On March 6, 2020, 35,107 July 2011 7,419 March 2015 June 30, 2020, no July 2011 March 2015 The key assumptions used to value the July 2011 December 31, 2019 As of December 31, Assumption 2019 Expected price volatility 115 % Expected term (in years) 0.18 Risk-free interest rate 1.52 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.44 As noted above, the Company issued warrants in connection with the October 2015 October 2015 480, 480 October 27, 2015 $1.3 The key assumptions used to value the October 2015 June 30, 2020 December 31, 2019 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 267 % 184 % Expected term (in years) 0.33 0.83 Risk-free interest rate 0.17 % 1.59 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.03 $ 0.49 During the second 2019, 158,400 158,400 July 2011 October 2015 $33 $0.4 $0.4 During the third 2019, 102,602 102,602 October 2015 $21 $0.2 $0.2 In August 2019, 1 4,198,566 4,198,566 “2019 2 2,700,000 “2019 3 167,942 “2019 12, August 2019 19, $0.99 2019 2019 The 2019 six $1.15. 19, 2019 2019 480 2019 2019 August 13, 2019 $3.1 The key assumptions used to value the 2019 August 13, 2019 As of August 13, Assumption 2019 Expected price volatility 149.29 % Expected term (in years) 5.50 Risk-free interest rate 1.58 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.75 The key assumptions used to value the 2019 June 30, 2020 December 31, 2019 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 178.79 % 154.10 % Expected term (in years) 4.63 5.13 Risk-free interest rate 0.27 % 1.70 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.09 $ 0.57 The 2019 $1.25. 19, 2019 2019 480. 2019 August 13, 2019 $124 The key assumptions used to value the 2019 August 13, 2019 As of August 13, Assumption 2019 Expected price volatility 155.19 % Expected term (in years) 5.00 Risk-free interest rate 1.57 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.74 The key assumptions used to value the 2019 June 30, 2020 December 31, 2019 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 183.79 % 159.94 % Expected term (in years) 4.11 4.61 Risk-free interest rate 0.24 % 1.69 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.08 $ 0.57 The 2019 October 9, 2019, $1.15. 19, 2019 480. 2019 August 13, 2019 $2.0 The key assumptions used to value the 2019 August 13, 2019 As of August 13, Assumption 2019 Expected price volatility 149.29 % Expected term (in years) 5.50 Risk-free interest rate 1.58 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.75 The key assumptions used to value the 2019 June 30, 2020 December 31, 2019 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 178.79 % 154.10 % Expected term (in years) 4.63 5.13 Risk-free interest rate 0.27 % 1.70 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.09 $ 0.57 The number of shares and fair value of the outstanding warrant liability as of June 30, 2020 Shares Warrant Liability Warrant liability - current October 2015 Warrants 38 $ 39 38 $ 39 Warrant liability – non-current 2019 Domestic Warrants 4,199 $ 4,567 2019 Foreign Warrants 2,700 2,937 2019 Ladenburg Warrants 168 181 7,067 $ 7,685

Note 12 - Stockholders' Equity

Note 12 - Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 12. Preferred Stock Under the Company's amended articles of incorporation, the Company is authorized to issue up to 5,000,000 may June 30, 2020 December 31, 2019, no On August 8, 2019, 2,700,000 2,700,000 1:1, October 9, 2019, 2,700,000 2,700,000 As the conversion trigger was dependent upon stockholder approval which is considered to be outside the control of the Company, the Series A Preferred Stock was considered to be contingently redeemable and as a result, was classified as mezzanine equity in the Company's interim balance sheet as of September 30, 2019. October 2019, The Company applied the fair value allocation methodology for allocating the proceeds of $2.7 first $2.0 11, China Kington served as placement agent in exchange for a commission equal to six 6% $162 $33 $93 $102 On October 9, 2019, 2,700,000 2,700,000 2,700,000 may 2,700,000 2019 $800 October 2019, December 31, 2019. Common Stock On May 27, 2020, 2020 50,000,000 75,000,000. On March 29, 2019, $3.0 90% five March 29, 2019 3 April 1, 2019 April 12, 2019. 150,000 second 2019, 1,747,312 $0.01 $360 $122 September 5, 2019, $288 no December 31, 2019 February 1, 2020. On June 26, 2019, 1,371,427 1,371,427 $2.4 three $1.0 $0.4 $1.0 six 6% $144,000. $27 On August 8, 2019, August 4,198,566 $1.00 August 4,198,566 4,198,566 $1.15. 19, $0.99. six 6% $252 2019 167,942 $1.25. 19, $0.99. $60 $312 August one six $2.00 10 may $2.00. 10, The Company applied the fair value allocation methodology for allocating the proceeds of $4.2 first $3.1 2019 11, In connection with the financing, the Company incurred issuance cost of $488 $233 $255 2019 $59 $65 On April 27, 2020, may $0.01 I.B.6. 3, $5,631,027. 8 April 27, 2020 June 15, 2020, three June 30, 2020, 5,836,792 $5.6 $0.4 On May 13, 2020, 1,000 $1 8, Stock Warrants In February 2016, July 2011, March 2015, October 2015 $1.81 May 2019, July 2011, March 2015, October 2015 $0.2061 March 2015 2017 11. March 2020, July 2011 March 2015 In May 2019, March 2015 $0.2061 $0.2061 1 March 2015 2 March 2015 820, $29 During the second 2019, 158,400 158,400 October 2015 $33 During the second 2019, 133,167 133,167 March 2015 133,167 70,000 64,979 $13 In June 2019, 1,371,427 1,371,427 one 1 $0.87, $1.00 In July 2019, 102,602 102,602 October 2015 $21 In August 2019, 4,198,566 4,198,566 six $1.15. 167,942 167,942 August 8, 2024, $1.25. 19, $0.99 In August 2019, 2,700,000 2,700,000 $1.15. 19, $0.99 During the first 2020, 70,000 70,000 March 2015 $14 On March 6, 2020, 35,107 July 2011 7,419 October 2015 June 30, 2020, no July 2011 March 2015 38,000 October 2015 October 27, 2020. During the first 2020, 228,571 228,571 June 2019 $199 six 6% $12 During the second 2020, 571,428 571,428 June 2019 $497 six 6% $29 On June 17, 2020, 571,428 June 2019 June 30, 2020, no June 2019 The details of all outstanding warrants as of June 30, 2020, Warrants Weighted- Average Exercise Price Outstanding at December 31, 2019 8,588 $ 1.09 Warrants granted - $ - Warrants exercised (870 ) $ 0.82 Warrants expired (613 ) $ 0.82 Outstanding at June 30, 2020 7,105 $ 1.15

Note 13 - Equity-based Compensa

Note 13 - Equity-based Compensation	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	NOTE 13. Equity Compensation Plans In October 2007, 2007 “2007 2007 80,000 2007 For the years from 2009 2012, 2007 40,000 4% 40,000, 37,427, 37,207 2007 January 2012, 2011 2010, 2013, 40,000 2007 4% 139,449, 82,461, 32,646, 59,157 2007 2016, 2015, 2014 2013, May 26, 2016, 2007 1,124,826 January 2017, 610,774 2007 2007 2007 2,318,486 March 15, 2017 ( 2007 Upon expiration of the 2007 2007 March 15, 2017 2007 may not 100% 10% not 110% 2007 no ten four In March 2017, 2017 “2017 June 2, 2017, 2017 not 2007 2017 2,318,486 first January 1, 2018 January 1, 2027 4% 4 2017 June 30, 2020, 3,044,090 2017 Under the terms of the 2017 may not 100% 10% not 110% not ten not five 10% four 2007 2017 Stock Option Summary The following table summarizes information about the Company's stock options outstanding at June 30, 2020, three (in thousands, except years and per share data) Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2019 2,183 $ 4.03 6.6 $ 43 Options granted 520 $ 0.97 Restricted stock units granted 160 $ — Options exercised - $ — Restricted stock units vested (3 ) $ — Options forfeited/cancelled (167 ) $ 5.83 Restricted stock units cancelled (1 ) $ — Outstanding at June 30, 2020 2,692 $ 3.10 6.97 $ 384 Vested and expected to vest at June 30, 2020 2,573 $ 3.20 6.84 $ 336 Vested at June 30, 2020 1,848 $ 4.04 5.85 $ — Exercisable at June 30, 2020 1,848 $ 4.04 5.85 $ — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's common stock as quoted on the NYSE American as of June 30, 2020 no three six June 30, 2020. 83 three six June 30, 2019 $189 no six June 30, 2019. As of June 30, 2020, $743 2.32 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, During the six June 30, 2020 2019, 520,000 125,000 The weighted-average assumptions used in determining the value of options are as follows: Six Months Ended June 30, Assumption 2020 2019 Expected price volatility 159.81 % 106.86 % Expected term (in years) 6.43 6.16 Risk-free interest rate 0.50 % 2.08 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 0.93 $ 0.27 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. In addition, during the six June 30, 2020, 160,000 six June 30, 2019, not For the three June 30, 2020 2019, $128 $116 six June 30, 2020 2019, $174 $223 In April 2019, April 29, 2019. three three $14 In May 2019, May 1, 2019. three three $7 In April 2020, April 1, 2020. three three $36 Stock-Based Awards to Non-Employees During the six June 30, 2020 2019, not When the Company grants stock options, the stock options are recorded at their fair value on the grant date and recognized over the respective service or vesting period. The fair value of the stock options that are granted is calculated using the Black-Scholes option pricing model as discussed above. In addition, during the six June 30, 2020 2019, not For the three June 30, 2020 2019, $2 $7 six June 30, 2020 2019, $9 $14 Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in results of operations for the options and restricted stock awards discussed above is as follows: Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2020 2019 2020 2019 Research and development $ 7 $ 13 $ 14 $ 24 Sales and marketing 11 27 20 46 General and administrative 108 83 149 167 Total stock-based compensation expense $ 126 $ 123 $ 183 $ 237 Since the Company has operating losses and net operating loss carryforwards, there are no

Note 14 - Revenue

Note 14 - Revenue	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 14. Revenue Transactions under the Company's major distribution agreements are recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. The Company records contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Milestone payments are included in the estimated transaction price when they are considered probable of being achieved. For license and collaboration revenue, the transaction price under license and collaboration arrangements, including upfront fees and milestone payments, are allocated differently to each performance obligation and may The following table presents changes in the Company's contract assets and liabilities for the six June 30, 2020 ( Balance at Beginning of the Period Additions Deductions Balance at the end of the Period (in thousands) Contract Liabilities: Deferred Revenue $ - $ 674 $ (559 ) $ 115 Contract Liabilities: Accrued Liabilities 434 1,020 (1,096 ) 358 Total $ 434 $ 1,694 $ (1,655 ) $ 473 During the six June 30, 2020 2019, Six Months Ended June 30, 2020 2019 Revenue recognized in the period from: Amounts included in contract liabilities at the beginning of the period: Performance obligations satisfied $ 434 $ 1,473 New activities in the period: Performance obligations satisfied 5,442 1,807 $ 5,876 $ 3,280 License, Collaboration and Distribution Agreements In January 2012, one $312,500. $312,500 January 2013, first December 31, 2014, $625,000 In September 2012, two 1 2 one one Pursuant to the terms of the Distribution Agreement, China Pioneer has the right to distribute NeutroPhase, upon a marketing approval from a Regulatory Authority, in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. China Pioneer is also obligated to make certain additional payments to the Company upon receipt of the marketing approval. The Distribution Agreement further provides that China Pioneer is entitled to a cumulative purchase discount not $500,000 Pursuant to the Purchase Agreement, we also received $2.5 one one two 1 800,000 September 2012; 2 1,200,000 October 2012, $1.25 $3.5 $2.5 $1.0 $600,000 In December 2013, 11 The Distribution Agreement and the Purchase Agreement expired on December 31, 2019. not On February 26, 2019, 0.025%. second 2020, $115 one June 30, 2020. During both the three six June 30, 2020, $5 three six June 30, 2019, $0 $41 During the three six June 30, 2020, $0 $173 three six June 30, 2019, $0 $209 As further described in Note 8, April 16, 2020, June 29, 2020. Avenova Distribution Agreements In November 2014, January 2015, April 2015, During the three June 30, 2020 2019, $0.4 $1.3 $0.9 $2.5 six June 30, 2020 2019, Under the prescription Avenova product distribution arrangements, the Company had a contract liability balance of $0.4 June 30, 2020 December 31, 2019. June 30, 2020 December 31, 2019 $0.1 $0.4 4, During 2019 June 30, 2020, 4 16. three June 30, 2020 2019, 4% 25% six June 30, 2020 2019, 7% 25% Avenova Direct In an effort to improve patient access, non-prescription Avenova Direct was launched on June 1, 2019 20mL three six June 30, 2020, $0.6 $1.4 three six June 30, 2019, KN95 The Company recently engaged in reselling KN95 KN95 $2.8 three June 30, 2020. KN95 $3.0 six June 30, 2020. no three six June 30, 2019.

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plan	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Retirement Benefits [Text Block]	NOTE 15. The Company has a 401 not no three six June 30, 2020 2019.

Note 16 - Related Party Transac

Note 16 - Related Party Transactions	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 16. Related Party Financing See Note 9, February 27, 2019, June 25, 2019 May 14, 2020 12, June 2019 August 2019. second 2020, $1.0 April 27, 2020, Related Party Revenue The Company recognized related party revenues from sales of NeutroPhase of $0 $173 three six June 30, 2020, $0 $90 three six June 30, 2020, $209 three six June 30, 2019. $176 three six June 30, 2019. $0 $41 three six June 30, 2019, second not three six June 30, 2020. 14, second There were no June 30, 2020 December 31, 2019, $173 first 2020 February 27, 2019. 9, Related Party Expenses During the three six June 30, 2020, KN95 June 30, 2020 December 31, 2019, $418 $0, The Company paid related party fees of $29 $144 three June 30, 2020 2019, $29 three June, 2020 June 2019 one $144 three June 30, 2019 three June 26, 2019. $144 $91 $214 six June 30, 2020 2019, $12 first 2020 June 2019 one $20 first 2019 $50 first 2020 2019, March 1, 2019. 9, 11, 12, As further described in Note 8, May 13, 2020, $75 three June 30, 2020 1,000 $1 12, Other Related Party Transactions During the second 2020, $79 0.5 one $79 4, As further described in Note 8, April 16, 2020, June 29, 2020.

Note 18 - Paycheck Protection P

Note 18 - Paycheck Protection Program	6 Months Ended
	Jun. 30, 2020
COVID 19 Member [Member]
Notes to Financial Statements
Unusual or Infrequent Items, or Both, Disclosure [Text Block]	NOTE 18. PAYCHECK PROTECTION PROGRAM On May 6, 2020, $901 March 27, 2020. The Loan, which was in the form of a Note (the "Note"), dated May 3, 2020, May 3, 2022 1.00% November 1, 2020. may no may 24 Since the Company determined that there is reasonable assurance that it will meet the conditions for forgiveness of the full loan amount, we accounted for the forgivable PPP Loan as a government grant that is earned through the entity's compliance with the loan forgiveness criteria. PPP proceeds received was accounted for as an income grant. A deferred income liability was recognized upon receipt of the forgivable loan proceeds. The deferred income liability will be recognized as other income as Qualifying Expenses are incurred. For the three six June 30, 2020, $469 June 30, 2020 December 31, 2019, $432 $0,

Note 19 - Subsequent Events

Note 19 - Subsequent Events	6 Months Ended
	Jun. 30, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 1 9 . SUBSEQUENT EVENTS Beginning on July 20, 2020, 2019 2019 2019 2019 1 2019 2019 $0.99 2 2019 $0.99 3 100% 2019 2019 $6.4 2019 2019 The New Warrants are exercisable six 6,898,566 $1.65 five Additionally, in relation to the Company's EmeryStation lease and Sublease Agreement, on August 4, 2020, 1 July 31, 2020 August 31, 2020 30 2 July 31, 2020, August 31, 2020 August 4, 2020, August 31, 2020.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.
Unaudited Interim Financial Information, Policy [Policy Text Block]	Unaudited Interim Financial Information The accompanying unaudited interim condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end condensed consolidated balance sheet data was derived from audited financial statements but does not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly-liquid instruments with a stated maturity of three June 30, 2020 December 31, 2019, The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets: June 30, December 31, 2020 2019 Cash and cash equivalents $ 8,775 $ 6,937 Restricted cash included in Other assets 475 475 Total cash, cash equivalents, and restricted cash in the statements of cash flows $ 9,250 $ 7,412 The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk and Major Partners Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with a highly-rated, major financial institution in the United States. Deposits in this bank may not During the three six June 30, 2020, 1 KN95 2 three During the three six June 30, 2020 2019, Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 KN95 Masks $ 2,839 $ — $ 3,012 $ — Avenova 1,140 1,580 2,686 3,030 Other products — 209 173 209 Total product revenue, net 3,979 1,789 5,871 3,239 Other revenue, net 5 — 5 41 Total sales, net $ 3,984 $ 1,789 $ 5,876 $ 3,280 The Company does not KN95 During the three six June 30, 2020 2019, 10% Three Months Ended June 30, Six Months Ended June 30, Major distribution or collaboration partner 2020 2019 2020 2019 Avenova Direct via Amazon 12 % * % 21 % * % Avenova distributor A * % 13 % * % 18 % Avenova distributor B * % 12 % * % 15 % Avenova distributor C * % 23 % * % 19 % *Not 10% As of June 30, 2020 December 31, 2019, 10% June 30, December 31, Major distribution or collaboration partner 2020 2019 Customer A from sales of KN95 Masks 52 % — % Avenova Direct via Amazon * % 20 % Avenova distributor A 12 % 28 % Avenova distributor B * % 13 % Avenova distributor C * % 19 % *Not 10% The Company relies on two not third may may not may 19
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Assets and Liabilities The Company's financial instruments include cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, related party notes payable, a convertible note, and warrants. The fair value of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and related party notes payable is carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Secured Convertible Promissory Note issued on March 26, 2019 ( The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures three may Level 1 Level 2 Level 3 Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it to be unlikely that specific invoices will be collected. Management identifies amounts due that are in dispute and it believes are unlikely to be collected. Management did not June 30, 2020. December 31, 2019, $51 120
Inventory, Policy [Policy Text Block]	Inventory Inventory is comprised of ( 1 2 3 June 30, 2020 December 31, 2019, $206 $247 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred.
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets and Operating Lease Right-of-Use Assets The Company accounts for long-lived assets and operating lease right-of-use assets in accordance with ASC 360, Property, Plant and Equipment may not first 2019, $125 no three six June 30, 2020.
Lessee, Leases [Policy Text Block]	Leases In February 2016, No. 2016 02, Leases (Topic 842 January 1, 2019. not At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not may The Company has elected to combine lease and non-lease components as a single component for all leases in which it is a lessee or a lessor. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current. As a result, as of the effective date, the Company no
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) ASC 220 , Comprehensive Income,
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition Revenue generated through the Company's webstore for Avenova and KN95 third Revenue generated through Amazon.com for Avenova and other products is recognized upon fulfillment by Amazon.com, which generally occurs upon delivery of the related products to a third The Company also generates Avenova product revenue through product sales to its major distribution partners and a limited number of partner pharmacies. Product supply of Avenova is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a “sell-in” basis. Upon recognition of product sales, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company does not not 30 one one Bulk orders of KN95 KN95
Cost of Goods Sold [Policy Text Block]	Cost of Goods Sold Cost of goods sold includes third
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include all costs associated with research, development and regulatory activities, including Emergency Use Authorization (“EUA”) submissions to the Food and Drug Administration (“FDA”). Research and development costs may no
Patent Costs Policy [Policy Text Block]	Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the condensed consolidated statements of operations and comprehensive loss.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company's stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these programs is recognized in the Company's condensed consolidated statements of stockholders' equity (deficit) based on their fair values as they are earned under the applicable vesting terms or the length of an offering period. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. See Note 13,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not
Warrant Liabilities [Policy Text Block]	Common Stock Warrant Liability The Company accounts for the issuance of common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 815, Derivatives and Hedging On January 1, 2019, 2017 11, Earnings Per Share (Topic 260 480 815 2017 11, March 31, 2019 $56 $56 $356 January 1, 2019, $356
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company computes net loss per share by presenting both basic and diluted earnings (loss) per share (“EPS”). Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During the three six June 30, 2020 2019, no The following table sets forth the calculation of basic and diluted EPS: Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator Net loss $ (4,482 ) $ (2,501 ) $ (6,064 ) $ (6,690 ) Less retained earning reduction related to down round feature triggered — (29 ) — (29 ) Net loss attributable to common stockholders $ (4,482 ) $ (2,530 ) $ (6,064 ) $ (6,719 ) Denominator Weighted average shares of common stock outstanding, basic and diluted 30,384 18,613 29,012 17,857 Net loss per share attributable to common stockholders, basic and diluted $ (0.15 ) $ (0.14 ) $ (0.21 ) $ (0.38 ) The following outstanding stock options and stock warrants were excluded from the diluted net loss per share computation, as their effect would have been anti-dilutive: As of June 30, (in thousands) 2020 2019 Period end stock options to purchase common stock 2,692 2,274 Period end common stock warrants 7,105 1,624 9,797 3,898 Shares underlying the Convertible Note were excluded from the EPS calculation as the Company intends to settle the Convertible Note in cash in lieu of stock pursuant to the securities purchase agreement, dated August 8, 2019, “August 12, August
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13 January 1, 2020 not In June 2016, 2016 13, Financial Instruments—Credit Losses (Topic 326 2016 13 2016 13 January 1, 2023. January 1, 2023. In December 2019, 2019 12, Income Taxes (Topic 740 2019 12 first 2021

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	June 30, December 31, 2020 2019 Cash and cash equivalents $ 8,775 $ 6,937 Restricted cash included in Other assets 475 475 Total cash, cash equivalents, and restricted cash in the statements of cash flows $ 9,250 $ 7,412
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 KN95 Masks $ 2,839 $ — $ 3,012 $ — Avenova 1,140 1,580 2,686 3,030 Other products — 209 173 209 Total product revenue, net 3,979 1,789 5,871 3,239 Other revenue, net 5 — 5 41 Total sales, net $ 3,984 $ 1,789 $ 5,876 $ 3,280
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, Major distribution or collaboration partner 2020 2019 2020 2019 Avenova Direct via Amazon 12 % * % 21 % * % Avenova distributor A * % 13 % * % 18 % Avenova distributor B * % 12 % * % 15 % Avenova distributor C * % 23 % * % 19 % June 30, December 31, Major distribution or collaboration partner 2020 2019 Customer A from sales of KN95 Masks 52 % — % Avenova Direct via Amazon * % 20 % Avenova distributor A 12 % 28 % Avenova distributor B * % 13 % Avenova distributor C * % 19 %
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Numerator Net loss $ (4,482 ) $ (2,501 ) $ (6,064 ) $ (6,690 ) Less retained earning reduction related to down round feature triggered — (29 ) — (29 ) Net loss attributable to common stockholders $ (4,482 ) $ (2,530 ) $ (6,064 ) $ (6,719 ) Denominator Weighted average shares of common stock outstanding, basic and diluted 30,384 18,613 29,012 17,857 Net loss per share attributable to common stockholders, basic and diluted $ (0.15 ) $ (0.14 ) $ (0.21 ) $ (0.38 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of June 30, (in thousands) 2020 2019 Period end stock options to purchase common stock 2,692 2,274 Period end common stock warrants 7,105 1,624 9,797 3,898

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements Using (in thousands) Balance at June 30, 2020 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Liabilities Warrant liability $ 7,724 $ — $ — $ 7,724 Embedded derivative liability 1 — — 1 Total liabilities $ 7,725 $ — $ — $ 7,725 Fair Value Measurements Using (in thousands) Balance at December 31, 2019 Quoted Prices in Active Markets for Identical Items (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Restricted cash held as a certificate of deposit $ 324 $ 324 $ — $ — Deposit held as a certificate of deposit 151 151 — — Total assets $ 475 $ 475 $ — $ — Liabilities Warrant liability $ 4,089 $ — $ — $ 4,089 Embedded derivative liability 3 — — 3 Total liabilities $ 4,092 $ — $ — $ 4,092
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands) Level 3 liabilities Fair value of warrant liability and embedded derivative liability at December 31, 2019 $ 4,092 Decrease in fair value of warrant liability at March 31, 2020 (122 ) Decrease in fair value of embedded derivative liability at March 31, 2020 (2 ) Decrease in fair value related to warrants expired (15 ) Fair value of warrant liability and embedded derivative liability at March 31, 2020 3,953 Increase in fair value of warrant liability at June 30, 2020 3,772 Fair value of warrant liability and embedded derivative liability at June 30, 2020 $ 7,725

Note 4 - Prepaid Expenses and_2

Note 4 - Prepaid Expenses and Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	(in thousands) June 30, December 31, 2020 2019 Prepaid insurance $ 455 $ 94 Prepaid sales rebates 142 401 Receivables from at-the-marketing offering 96 — Related party receivables 79 — Prepaid inventory 73 — Prepaid security deposit for lease 65 65 Prepaid patents 44 85 Prepaid dues and subscription 31 82 Retainer 17 46 Other 114 113 Total prepaid expenses and other current assets $ 1,116 $ 886

Note 5 - Inventory (Tables)

Note 5 - Inventory (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(in thousands) June 30, December 31, 2020 2019 Raw materials and supplies $ 180 $ 185 Finished goods 652 554 Less: Reserve for excess and obsolete inventory (206 ) (247 ) Total inventory, net $ 626 $ 492

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	(in thousands) June 30, December 31, 2020 2019 Office and laboratory equipment $ 20 $ 20 Furniture and fixtures 157 157 Computer equipment and software 343 349 Production equipment 65 65 Leasehold improvements 79 79 Total property and equipment, at cost 664 670 Less: accumulated depreciation and amortization (580 ) (560 ) Total property and equipment, net $ 84 $ 110

Note 7 - Accrued Liabilities (T

Note 7 - Accrued Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	(in thousands) June 30, December 31, 2020 2019 Avenova contract liabilities $ 478 $ 822 Employee payroll and benefits 237 463 Consulting service 210 109 Sublease security deposit 198 198 Prepaid rent from subleasee 118 — Related party consulting service — 33 Other 41 153 Total accrued liabilities $ 1,282 $ 1,778

Note 8 - Commitments and Cont_2

Note 8 - Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Lease, Cost [Table Text Block]	Lease Costs Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 Operating lease cost $ 250 $ 276 $ 514 $ 588 Sublease income (158 ) (158 ) (316 ) (316 ) Net lease cost $ 92 $ 118 $ 198 $ 272 Other information Operational cash flow used for operating leases $ 284 $ 324 $ 580 $ 648 June 30, 2020 2019 Weighted-average remaining lease term (in years) 1.4 2.0 Weighted-average discount rate 12 % 12 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Remaining in 2020 $ 461 2021 454 2022 88 Thereafter — Total future minimum lease payments 1,003 Less imputed interest (81 ) Total $ 922 Reported as: Operating lease liability $ 619 Operating lease liability- non-current 303 Total $ 922

Note 10 - Convertible Note (Tab

Note 10 - Convertible Note (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	As of Assumption March 26, 2019 Stock price (latest bid price) $ 1.28 Equity volatility 93.8 % Risk-free interest rate 2.34 % Remaining term 1.5 Assumption As of December 31, 2019 Stock price $ 0.65 Equity volatility 192.6 % Risk-free interest rate 1.60 % Remaining term 0.74
Convertible Debt [Table Text Block]	(in thousands) Principal amount $ 419 Unamortized discount (1 ) Total debt 418 Less: short-term 418 Long-term $ —
Schedule of Maturities of Long-term Debt [Table Text Block]	(in thousands) 2020 $ 419 2021 and thereafter — Total $ 419

Note 11 - Warrant Liability (Ta

Note 11 - Warrant Liability (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Derivative Instruments [Table Text Block]	As of December 31, Assumption 2019 Expected price volatility 115 % Expected term (in years) 0.18 Risk-free interest rate 1.52 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.44 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 267 % 184 % Expected term (in years) 0.33 0.83 Risk-free interest rate 0.17 % 1.59 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.03 $ 0.49 As of August 13, Assumption 2019 Expected price volatility 149.29 % Expected term (in years) 5.50 Risk-free interest rate 1.58 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.75 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 178.79 % 154.10 % Expected term (in years) 4.63 5.13 Risk-free interest rate 0.27 % 1.70 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.09 $ 0.57 As of August 13, Assumption 2019 Expected price volatility 155.19 % Expected term (in years) 5.00 Risk-free interest rate 1.57 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.74 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 183.79 % 159.94 % Expected term (in years) 4.11 4.61 Risk-free interest rate 0.24 % 1.69 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.08 $ 0.57 As of August 13, Assumption 2019 Expected price volatility 149.29 % Expected term (in years) 5.50 Risk-free interest rate 1.58 % Dividend yield 0.00 % Weighted-average fair value of warrants $ 0.75 As of June 30, December 31, Assumption 2020 2019 Expected price volatility 178.79 % 154.10 % Expected term (in years) 4.63 5.13 Risk-free interest rate 0.27 % 1.70 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 1.09 $ 0.57
Class of Warrant or Right [Table Text Block]	Shares Warrant Liability Warrant liability - current October 2015 Warrants 38 $ 39 38 $ 39 Warrant liability – non-current 2019 Domestic Warrants 4,199 $ 4,567 2019 Foreign Warrants 2,700 2,937 2019 Ladenburg Warrants 168 181 7,067 $ 7,685

Note 12 - Stockholders' Equit_2

Note 12 - Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Weighted- Average Exercise Price Outstanding at December 31, 2019 8,588 $ 1.09 Warrants granted - $ - Warrants exercised (870 ) $ 0.82 Warrants expired (613 ) $ 0.82 Outstanding at June 30, 2020 7,105 $ 1.15

Note 13 - Equity-based Compen_2

Note 13 - Equity-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	(in thousands, except years and per share data) Options Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2019 2,183 $ 4.03 6.6 $ 43 Options granted 520 $ 0.97 Restricted stock units granted 160 $ — Options exercised - $ — Restricted stock units vested (3 ) $ — Options forfeited/cancelled (167 ) $ 5.83 Restricted stock units cancelled (1 ) $ — Outstanding at June 30, 2020 2,692 $ 3.10 6.97 $ 384 Vested and expected to vest at June 30, 2020 2,573 $ 3.20 6.84 $ 336 Vested at June 30, 2020 1,848 $ 4.04 5.85 $ — Exercisable at June 30, 2020 1,848 $ 4.04 5.85 $ —
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, (in thousands) 2020 2019 2020 2019 Research and development $ 7 $ 13 $ 14 $ 24 Sales and marketing 11 27 20 46 General and administrative 108 83 149 167 Total stock-based compensation expense $ 126 $ 123 $ 183 $ 237
Employees and Directors [Member]
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Six Months Ended June 30, Assumption 2020 2019 Expected price volatility 159.81 % 106.86 % Expected term (in years) 6.43 6.16 Risk-free interest rate 0.50 % 2.08 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 0.93 $ 0.27

Note 14 - Revenue (Tables)

Note 14 - Revenue (Tables)	6 Months Ended
	Jun. 30, 2020
Notes Tables
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Balance at Beginning of the Period Additions Deductions Balance at the end of the Period (in thousands) Contract Liabilities: Deferred Revenue $ - $ 674 $ (559 ) $ 115 Contract Liabilities: Accrued Liabilities 434 1,020 (1,096 ) 358 Total $ 434 $ 1,694 $ (1,655 ) $ 473
Disaggregation of Revenue [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2020 2019 2020 2019 KN95 Masks $ 2,839 $ — $ 3,012 $ — Avenova 1,140 1,580 2,686 3,030 Other products — 209 173 209 Total product revenue, net 3,979 1,789 5,871 3,239 Other revenue, net 5 — 5 41 Total sales, net $ 3,984 $ 1,789 $ 5,876 $ 3,280

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Accounts Receivable, Allowance for Credit Loss, Ending Balance						$ 51
Allowance for Doubtful Accounts, Past Due Period Threshold (Day)				120 days
Inventory Valuation Reserves, Ending Balance	$ 206			$ 206		247
Operating Lease, Impairment Loss	0		$ 125	0	$ 125
Payment for Product Supply Period (Day)		30 days
Additional Paid in Capital, Ending Balance	131,725			131,725		125,718
Stockholders' Equity Attributable to Parent, Ending Balance	983	$ (349)	1,129	983	1,669	973		$ 4,954
Retained Earnings [Member]
Stockholders' Equity Attributable to Parent, Ending Balance	$ (131,088)	$ (126,606)	(119,526)	$ (131,088)	$ (122,056)	$ (125,024)		$ (114,981)
Accounting Standards Update 2017-11 [Member]
Additional Paid in Capital, Ending Balance			56				$ 356
Warrants and Rights Outstanding			$ (56)
Accounting Standards Update 2017-11 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member] | Retained Earnings [Member]
Stockholders' Equity Attributable to Parent, Ending Balance							$ (356)
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)				5 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)				7 years
Computer Equipment and Software [Member]
Property, Plant and Equipment, Useful Life (Year)				3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)				7 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)				7 years

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash and cash equivalents	$ 8,775	$ 6,937
Restricted cash included in Other assets	475	475
Total cash, cash equivalents, and restricted cash in the statements of cash flows	$ 9,250	$ 7,412	$ 4,143	$ 3,658

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total sales, net	$ 3,984	$ 1,789	$ 5,876	$ 3,280
KN95 Masks [Member]
Total sales, net	2,839		3,012
Avenova Product [Member]
Total sales, net	1,140	1,580	2,686	3,030
Other Products [member]
Total sales, net		209	173	209
Total Product Revenue [Member]
Total sales, net	3,979	1,789	5,871	3,239
Product and Service, Other [Member]
Total sales, net	$ 5		$ 5	$ 41

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended				6 Months Ended				12 Months Ended
	Jun. 30, 2020		Jun. 30, 2019		Jun. 30, 2020		Jun. 30, 2019		Dec. 31, 2019
Revenue from Contract with Customer Benchmark [Member] | Avenova Direct [Member]
Distribution or collaboration partners	12.00%			[1]	21.00%			[1]
Revenue from Contract with Customer Benchmark [Member] | Distributor A [Member]
Distribution or collaboration partners		[1]	13.00%			[1]	18.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor B [Member]
Distribution or collaboration partners		[1]	12.00%			[1]	15.00%
Revenue from Contract with Customer Benchmark [Member] | Distributor C [Member]
Distribution or collaboration partners		[1]	23.00%			[1]	19.00%
Accounts Receivable [Member] | Avenova Direct [Member]
Distribution or collaboration partners						[1]			20.00%
Accounts Receivable [Member] | Customer A from sales of KN95 [Member]
Distribution or collaboration partners					52.00%
Accounts Receivable [Member] | Distributor A [Member]
Distribution or collaboration partners					12.00%				28.00%
Accounts Receivable [Member] | Distributor B [Member]
Distribution or collaboration partners						[1]			13.00%
Accounts Receivable [Member] | Distributor C [Member]
Distribution or collaboration partners						[1]			19.00%
[1]	Not greater than 10%

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Net loss	$ (4,482,000)	$ (1,582,000)	$ (2,501,000)	$ (4,189,000)	$ (6,064,000)	$ (6,690,000)
Less retained earning reduction related to down round feature triggered			(29,000)			(29,000)
Net loss attributable to common stockholders	$ (4,482)		$ (2,530)		$ (6,064)	$ (6,719)
Weighted average shares of common stock outstanding, basic and diluted (in shares)	30,384		18,613		29,012	17,857
Net loss per share attributable to common stockholders (basic and diluted) (in dollars per share)	$ (0.15)		$ (0.14)		$ (0.21)	$ (0.38)

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Anti-dilutive securities (in shares)	9,797	3,898
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	2,692	2,274
Warrant [Member]
Anti-dilutive securities (in shares)	7,105	1,624

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 06, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Fair Value Adjustment of Warrants		$ 3,772	$ 487	$ 3,635	$ 544
The July 2011 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)	35,107			35,107
Fair Value Adjustment of Warrants				$ (15)

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Restricted cash held as a certificate of deposit	$ 324	$ 324
Deposit held as a certificate of deposit	151	151
Total assets	475	475
Warrant liability	7,724	4,089
Embedded derivative liability	1	3
Total liabilities	7,725	4,092
Fair Value, Inputs, Level 1 [Member]
Restricted cash held as a certificate of deposit	324	324
Deposit held as a certificate of deposit	151	151
Total assets	475	475
Warrant liability
Embedded derivative liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability
Embedded derivative liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Restricted cash held as a certificate of deposit
Deposit held as a certificate of deposit
Total assets
Warrant liability	7,724	4,089
Embedded derivative liability	1	3
Total liabilities	$ 7,725	$ 4,092

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020
Balance	$ 3,953	$ 4,092
Balance	7,725	3,953
Warrant Liability [Member]
Increase (decrease) in fair value of liability	$ 3,772	(122)
Embedded Derivative Liability [Member]
Increase (decrease) in fair value of liability		(2)
Expiration of Warrants [Member]
Increase (decrease) in fair value of liability		$ (15)

Note 4 - Prepaid Expenses and_3

Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Prepaid insurance	$ 455	$ 94
Prepaid sales rebates	142	401
Receivables from at-the-marketing offering	96
Related party receivables	79
Prepaid inventory	73
Prepaid security deposit for lease	65	65
Prepaid patents	44	85
Prepaid dues and subscription	31	82
Retainer	17	46
Other	114	113
Total prepaid expenses and other current assets	$ 1,116	$ 886

Note 5 - Inventory - Summary of

Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Raw materials and supplies	$ 180	$ 185
Finished goods	652	554
Less: Reserve for excess and obsolete inventory	(206)	(247)
Total inventory, net	$ 626	$ 492

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Depreciation, Depletion and Amortization, Total	$ 14	$ 16	$ 28	$ 33

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property and equipment, at cost	$ 664	$ 670
Less: accumulated depreciation and amortization	(580)	(560)
Total property and equipment, net	84	110
Equipment [Member]
Property and equipment, at cost	20	20
Furniture and Fixtures [Member]
Property and equipment, at cost	157	157
Computer Equipment and Software [Member]
Property and equipment, at cost	343	349
Production Equipment [Member]
Property and equipment, at cost	65	65
Leasehold Improvements [Member]
Property and equipment, at cost	$ 79	$ 79

Note 7 - Accrued Liabilities -

Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Avenova contract liabilities	$ 478	$ 822
Employee payroll and benefits	237	463
Consulting service	210	109
Sublease security deposit	198	198
Prepaid rent from subleasee	118
Related party consulting service		33
Other	41	153
Total accrued liabilities	$ 1,282	$ 1,778

Note 8 - Commitments and Cont_3

Note 8 - Commitments and Contingencies (Details Textual) $ / shares in Units, shares in Millions	Jul. 29, 2019USD ($)	Jun. 30, 2020USD ($)$ / shares	Dec. 31, 2019$ / shares	Mar. 31, 2019USD ($)	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)	Dec. 31, 2019USD ($)$ / shares	May 13, 2020$ / sharesshares	Jul. 31, 2011$ / shares
Number of Vehicles Leased			15
Operating Lease, Impairment Loss		$ 0		$ 125,000	$ 0	$ 125,000
Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year		$ 194,000			$ 194,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 1.15	$ 1.09		$ 1.15		$ 1.09		$ 33.25
TLF Bio Innovation, Related Party Warrants [Member]
Class of Warrant or Right, Number of Securities Callable by Warrants or Rights upon Completion of Certain Conditions (in shares) | shares								2
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares								$ 0.865
Warrants in Connection with Microprofit Agreement [Member]
Class of Warrant or Right, Number of Securities Callable by Warrants or Rights Represented as Percentage of Company’s Outstanding Common Stock								12.00%
Selling and Marketing Expense [Member]
Operating Lease, Impairment Loss							$ 125,000
Master Fleet Lease Agreement [Member]
Number of Vehicles Leased							54
Lessee, Operating Lease, Term of Contract (Month)			3 years				3 years
KBSIII Towers [Member]
Lessee, Operating Lease, Renewal Term (Year)		5 years			5 years
Chief Executive Officer [Member]
Severance Costs	$ 370,000

Note 8 - Commitments and Cont_4

Note 8 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating lease cost	$ 250	$ 276	$ 514	$ 588
Sublease income	(158)	(158)	(316)	(316)
Net lease cost	92	118	198	272
Operational cash flow used for operating leases	$ 284	$ 324	$ 580	$ 648
Weighted-average remaining lease term (in years) (Year)	1 year 146 days	2 years	1 year 146 days	2 years
Weighted-average discount rate	12.00%	12.00%	12.00%	12.00%

Note 8 - Commitments and Cont_5

Note 8 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Remaining in 2020	$ 461
2021	454
2022	88
Thereafter
Total future minimum lease payments	1,003
Less imputed interest	(81)
Total	922
Operating lease liability	619	$ 930
Operating lease liability- non-current	303	$ 505
Total	$ 922

Note 9 - Related Party Notes _2

Note 9 - Related Party Notes Payable (Details Textual) - USD ($) $ in Thousands	May 15, 2020	Jun. 25, 2019	Feb. 27, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Notes Payable, Related Parties, Current				$ 104		$ 104		$ 1,202
Pioneer Hong Kong [Member] | Promissory Note [Member]
Debt Instrument, Face Amount			$ 1,000
Debt Instrument, Periodic Payment, Interest		$ 300	150
Repayments of Long-term Debt, Total	$ 1,000
Notes Payable, Related Parties, Current				104		104
Debt Issuance Costs, Net, Total			$ 20
Interest Expense, Total				$ 27	$ 98	$ 75	$ 130
China Kington [Member]
Brokering Fee, Percent			2.00%
Consulting Agreement, Term (Year)			1 year
Director Bob Wu [Member]
Consulting Agreement, Amount			$ 100

Note 10 - Convertible Note (Det

Note 10 - Convertible Note (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Aug. 08, 2019	Mar. 26, 2019	Jun. 30, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Aug. 31, 2019	Oct. 27, 2015
Proceeds from Convertible Debt									$ 2,000
Stock Issued During Period, Shares, New Issues (in shares)	4,198,566			4,198,566
Shares Issued, Price Per Share (in dollars per share)	$ 1										$ 5
Repayments of Convertible Debt							1,145
Warrant Exercisable for Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	4,198,566
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	4,198,566									4,198,566
Common Stock, Closing Price (in dollars per share)	$ 2
Iliad Research and Trading, L.P. [Member]
Payments for Redeeming of Convertible Note, Per Month								$ 200
Repayments of Convertible Debt			$ 600				1,200
Repayments of Convertible Debt, Against Outstanding Balance			579				1,100
Iliad Research and Trading, L.P. [Member] | Secured Convertible Promissory Note [member]
Debt Instrument, Face Amount		$ 2,200	$ 419				$ 419
Debt Instrument, Interest Rate, Stated Percentage		10.00%
Proceeds from Convertible Debt		$ 2,000
Debt Instrument, Original Issue Discount		200
Debt Instrument, Fee Amount		15
Deferred Finance Costs Excluding Transaction Fees		$ 182
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.65
Debt Instrument, Convertible, Redeemed Amount Per Month		$ 200		$ 200
Debt Instrument, Convertible, Market Price, Percentage of Lowest Closing Bid Price		85.00%
Debt Instrument, Redemption Price, Percentage		115.00%
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		3,200,000
Debt Instrument, Convertible, Increase in Outstanding Balance, Percentage		15.00%
Embedded Derivative, Fair Value of Embedded Derivative Liability		$ 400
Debt Instrument, Unamortized Discount, Including Original Issue Discount, Total		627
Debt Issuance Cost, Gross, Noncurrent		$ 197
Debt Instrument, Interest Rate During Period			37.00%			54.00%	43.00%
Interest Expense, Debt, Total			$ 59		$ 302		$ 199		$ 322

Note 10 - Convertible Note - Ke

Note 10 - Convertible Note - Key Assumptions Used to Value the Combined Embedded Derivative (Details)	Dec. 31, 2019yr	Mar. 26, 2019yr
Measurement Input, Share Price [Member]
Derivative Liability, Measurement Input	0.0065	0.0128
Measurement Input, Price Volatility [Member]
Derivative Liability, Measurement Input	1.926	0.938
Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	0.016	0.0234
Measurement Input, Expected Term [Member]
Derivative Liability, Measurement Input	0.74	1.5

Note 10 - Convertible Note - Sc

Note 10 - Convertible Note - Schedule of Convertible Note (Details) - Secured Convertible Promissory Note [member] - Iliad Research and Trading, L.P. [Member] - USD ($) $ in Thousands	Jun. 30, 2020	Mar. 26, 2019
Debt Instrument, Face Amount	$ 419	$ 2,200
Unamortized discount	(1)
Long-term	418
Less: short-term	418
Long-term

Note 10 - Convertible Note - _2

Note 10 - Convertible Note - Schedule of Maturity of Convertible Note (Details) - Iliad Research and Trading, L.P. [Member] - Secured Convertible Promissory Note [member] $ in Thousands	Jun. 30, 2020USD ($)
2020	$ 419
2021 and thereafter
Total	$ 419

Note 11 - Warrant Liability (De

Note 11 - Warrant Liability (Details Textual) - USD ($)	Jul. 20, 2020	Mar. 06, 2020	Aug. 08, 2019	Oct. 27, 2015	Oct. 22, 2015	Mar. 03, 2015	Oct. 31, 2015	Jul. 31, 2011	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Oct. 09, 2019	Aug. 31, 2019	Aug. 13, 2019	May 31, 2019	Feb. 29, 2016	Jan. 05, 2012
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued (in shares)								139,520
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)								$ 33.25				$ 1.15		$ 1.09
Minimum Common Stock Closing Bid Price Per Share (in dollars per share)																				$ 66.50
Stock Issued During Period, Shares, New Issues (in shares)			4,198,566							4,198,566
Shares Issued, Price Per Share (in dollars per share)			$ 1	$ 5
Class of Warrant or Right, Exercised During Period (in shares)												870,000
Proceeds from Warrant Exercises												$ 669,000	$ 46,000
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity													$ 400,000
Subsequent Event [Member]
Proceeds from Warrant Exercises	$ 6,400,000
Underwriting Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 5
Warrants and Rights Outstanding, Term (Month)				5 years
Stock Issued During Period, Shares, New Issues (in shares)				492,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				442,802
Proceeds from Issuance of Stock and Warrants				$ 2,100,000
Warrants and Rights Outstanding				$ 1,300,000
March 2015 Short-term and Long-term Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																		$ 0.2061
Length of Notice for warrant Holders (Day)						20 days	2 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)									70,000		133,167		133,167
Class of Warrant or Right, Exercised During Period (in shares)									70,000		133,167
Proceeds from Warrant Exercises									$ 14,000		$ 13,000
Short-term Warrants [Member] | Private Placement [Member]
Warrants and Rights Outstanding, Term (Month)					1 year 90 days
Long-term Warrants [Member] | Private Placement [Member]
Warrants and Rights Outstanding, Term (Month)					5 years
The 2011 and March 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 5
Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger (in dollars per share)					$ 5
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																		$ 0.2061	$ 1.81
The July 2011 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)		35,107										35,107
Warrants and Rights Outstanding									0
The March 2015 Warrants [Member]
Class of Warrant or Right, Expired During Period (in shares)		7,419
July 2011 and October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										102,602	158,400		158,400
Warrants and Rights Outstanding										$ 200,000	$ 400,000		$ 400,000
Class of Warrant or Right, Exercised During Period (in shares)										102,602	158,400
Proceeds from Warrant Exercises										$ 21,000	$ 33,000
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity										$ 200,000	$ 400,000
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.15													$ 1.15	$ 1.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			4,198,566													4,198,566
Warrants and Rights Outstanding			$ 3,100,000						4,567,000								$ 3,100,000
The 2019 Domestic Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.99
The 2019 Foreign Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)															$ 1.15	$ 1.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			2,700,000												2,700,000	2,700,000
Warrants and Rights Outstanding			$ 2,000,000						2,937,000								$ 2,000,000
The 2019 Foreign Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	0.99
The 2019 Ladenburg Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 1.25													$ 1.25	$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)																167,942
Warrants and Rights Outstanding									$ 181,000								$ 124,000
The 2019 Ladenburg Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.99

Note 11 - Warrant Liability - T

Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details)	Jun. 30, 2020	Dec. 31, 2019	Aug. 13, 2019
Measurement Input, Price Volatility [Member] | The 2011 Warrants [Member]
Warrants assumptions		1.15
Measurement Input, Price Volatility [Member] | October 2015 Warrants [Member]
Warrants assumptions	2.67	1.84
Measurement Input, Price Volatility [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	1.7879	1.541	1.4929
Measurement Input, Price Volatility [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	1.8379	1.5994	1.5519
Measurement Input, Price Volatility [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	1.7879	1.541	1.4929
Measurement Input, Expected Term [Member] | The 2011 Warrants [Member]
Warrants assumptions		0.18
Measurement Input, Expected Term [Member] | October 2015 Warrants [Member]
Warrants assumptions	0.33	0.83
Measurement Input, Expected Term [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	4.63	5.13	5.5
Measurement Input, Expected Term [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	4.11	4.61	5
Measurement Input, Expected Term [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	4.63	5.13	5.5
Measurement Input, Risk Free Interest Rate [Member] | The 2011 Warrants [Member]
Warrants assumptions		0.0152
Measurement Input, Risk Free Interest Rate [Member] | October 2015 Warrants [Member]
Warrants assumptions	0.0017	0.0159
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	0.0027	0.017	0.0158
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	0.0024	0.0169	0.0157
Measurement Input, Risk Free Interest Rate [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	0.0027	0.017	0.0158
Measurement Input, Expected Dividend Rate [Member] | The 2011 Warrants [Member]
Warrants assumptions		0
Measurement Input, Expected Dividend Rate [Member] | October 2015 Warrants [Member]
Warrants assumptions	0	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Expected Dividend Rate [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	0	0	0
Measurement Input, Share Price [Member] | The 2011 Warrants [Member]
Warrants assumptions		0.0044
Measurement Input, Share Price [Member] | October 2015 Warrants [Member]
Warrants assumptions	0.0103	0.0049
Measurement Input, Share Price [Member] | The 2019 Domestic Warrants [Member]
Warrants assumptions	0.0109	0.0057	0.0075
Measurement Input, Share Price [Member] | The 2019 Ladenburg Warrants [Member]
Warrants assumptions	0.0108	0.0057	0.0074
Measurement Input, Share Price [Member] | The 2019 Foreign Warrants [Member]
Warrants assumptions	0.0109	0.0057	0.0075

Note 11 - Warrant Liability - O

Note 11 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($) shares in Thousands	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Aug. 13, 2019	Aug. 08, 2019
Shares (in shares)	7,105		8,588
The 2011 Warrants [Member]
Shares (in shares)		38
Warrant liability		$ 39,000
Warrant Liability, Current [Member]
Shares (in shares)		38
Warrant liability		$ 39,000
The 2019 Domestic Warrants [Member]
Shares (in shares)		4,199
Warrant liability		$ 4,567,000		$ 3,100,000	$ 3,100,000
The 2019 Foreign Warrants [Member]
Shares (in shares)		2,700
Warrant liability		$ 2,937,000		2,000,000	$ 2,000,000
The 2019 Ladenburg Warrants [Member]
Shares (in shares)		168
Warrant liability		$ 181,000		$ 124,000
Warrant Liability, Noncurrent [Member]
Shares (in shares)		7,067
Warrant liability		$ 7,685,000

Note 12 - Stockholders' Equit_3

Note 12 - Stockholders' Equity (Deficit) (Details Textual) - USD ($)	Jul. 20, 2020	Jun. 17, 2020	May 13, 2020	Mar. 06, 2020	Oct. 09, 2019	Sep. 05, 2019	Aug. 08, 2019	Jun. 26, 2019	Mar. 29, 2019	Aug. 31, 2019	Jul. 31, 2019	Jun. 30, 2019	May 31, 2019	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Apr. 27, 2020	Dec. 31, 2019	Aug. 13, 2019	Feb. 29, 2016	Oct. 27, 2015	Jul. 31, 2011
Preferred Stock, Shares Authorized (in shares)														5,000,000				5,000,000			5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)														0				0			0
Stock Issued During Period, Shares, New Issues (in shares)							4,198,566									4,198,566
Payments of Stock Issuance Costs							$ 488,000
Common Stock, Shares Authorized (in shares)														75,000,000				75,000,000			50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)														$ 0.01				$ 0.01		$ 0.01	$ 0.01
Stock Issued During Period, Value, New Issues																	$ 2,467,000
Proceeds from Issuance of Common Stock							$ 4,200,000											$ 5,220,000	$ 2,467,000
Shares Issued, Price Per Share (in dollars per share)							$ 1																	$ 5
Class of Warrant or Right, Issued During Period (in shares)
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)														$ 1.15				$ 1.15			$ 1.09				$ 33.25
Additional Paid in Capital, Ending Balance														$ 131,725,000				$ 131,725,000			$ 125,718,000
Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount																	$ (29,000)		(29,000)
Class of Warrant or Right, Exercised During Period (in shares)																		870,000
Proceeds from Warrant Exercises																		$ 669,000	$ 46,000
Class of Warrant or Right, Outstanding (in shares)														7,105,000				7,105,000			8,588,000
TLF Bio Innovation [Member]
Stock Issued During Period, Shares, New Issues (in shares)			1,000
Proceeds from Issuance of Common Stock			$ 1,000
Subsequent Event [Member]
Proceeds from Warrant Exercises	$ 6,400,000
Conversion of Series A Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					2,700,000
Conversion of Stock, Shares Issued (in shares)					2,700,000
Triton Funds LP [Member]
Common Stock, Shares Authorized (in shares)									3,000,000
Purchase Price, Percentage of Lowest Trading Price of Common Stock for Five Days Prior to Closing									90.00%
Sale of Stock, Price Per Share (in dollars per share)													$ 0.2061
Triton Funds LLC [Member]
Stock Issued During Period, Shares, New Issues (in shares)									150,000								1,747,312
Payments of Stock Issuance Costs																	$ 122,000
Common Stock, Par or Stated Value Per Share (in dollars per share)												$ 0.01					$ 0.01		$ 0.01
Stock Issued During Period, Value, New Issues																	$ 360,000
Proceeds from Issuance of Common Stock						$ 288,000
Ladenburg Thalmann and Co. Inc. [Member]
Private Placement, Commission Percentage							6.00%
Payments of Stock Issuance Costs							$ 252,000
Payments of Stock Issuance Costs, Reimbursement of Expenses							60,000
Payments of Stock Issuance Costs, Other							312,000
Private Placement [Member]
Payments of Stock Issuance Costs							33,000	$ 27,000
Payments of Stock Issuance Costs Allocated to Warrants							$ 93,000
Private Placement [Member] | China Kington Asset Management Co. Ltd. [Member]
Private Placement, Commission Percentage							6.00%
Payments of Stock Issuance Costs							$ 162,000
Private Placement [Member] | Three Accredited Investors [Member]
Stock Issued During Period, Shares, New Issues (in shares)								1,371,427
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								1,371,427
Issuance of Stock and Warrants During the Period, Value								$ 2,400,000
Private Placement [Member] | Xiao Rui Liu [Member]
Issuance of Stock and Warrants During the Period, Value								1,000,000
Private Placement [Member] | Hai Dong Pang [Member]
Issuance of Stock and Warrants During the Period, Value								400,000
Private Placement [Member] | Ping Huang [Member]
Issuance of Stock and Warrants During the Period, Value								$ 1,000,000
Private Placement [Member] | China Kington [Member]
Private Placement, Commission Percentage								6.00%
Payments of Stock Issuance Costs								$ 144,000
ATM Program [Member]
Stock Issued During Period, Shares, New Issues (in shares)														5,836,792
Payments of Stock Issuance Costs														$ 400,000
Stock Issued During Period, Value, New Issues														5,220,000
Proceeds from Issuance of Common Stock														$ 5,600,000
ATM Program, Maximum Common Stock Sales																				$ 5,631,027
The 2019 Foreign Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,700,000		2,700,000			2,700,000
Warrants and Rights Outstanding							$ 2,000,000								$ 2,937,000							$ 2,000,000
Class of Warrant or Right, Issued During Period (in shares)										2,700,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.15					$ 1.15
Class of Warrant or Right, Outstanding (in shares)															2,700,000
The 2019 Foreign Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.99
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							4,198,566			4,198,566
Warrants and Rights Outstanding							$ 3,100,000								$ 4,567,000							$ 3,100,000
Payments of Stock Issuance Costs Allocated to Warrants							$ 233,000
Class of Warrant or Right, Issued During Period (in shares)							4,198,566			4,198,566
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 1.15			$ 1.15												$ 1.15
Common Stock, Closing Price (in dollars per share)							$ 2
Additional Paid in Capital, Ending Balance							$ (255,000)
Class of Warrant or Right, Outstanding (in shares)															4,199,000
The 2019 Domestic Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	0.99
The 2019 Ladenburg Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)										167,942
Warrants and Rights Outstanding															$ 181,000							$ 124,000
Payments of Stock Issuance Costs Allocated to Warrants							59,000
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							$ 65,000
Class of Warrant or Right, Issued During Period (in shares)										167,942
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 1.25			$ 1.25												$ 1.25
Class of Warrant or Right, Outstanding (in shares)															168,000
The 2019 Ladenburg Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.99
The 2019 Ladenburg Warrants [Member] | Ladenburg Thalmann and Co. Inc. [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							167,942
July 2011, March 2015, and October 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													0.2061										$ 1.81
March 2015 Short-term and Long-term Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												133,167			70,000		133,167		133,167
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.2061
Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount													$ 29,000
Class of Warrant or Right, Exercised During Period (in shares)															70,000		133,167
Proceeds from Warrant Exercises															$ 14,000		$ 13,000
Class of Warrant or Right, Exercised During Period, Cashless Exercise (in shares)																	70,000
Stock Issued In Connection with Exercise of Warrants, Shares (in shares)																	64,979
March 2015 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.2061
October 2015 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)											102,602	158,400					158,400		158,400
Class of Warrant or Right, Exercised During Period (in shares)											102,602						158,400
Proceeds from Warrant Exercises											$ 21,000						$ 33,000
Class of Warrant or Right, Expired During Period (in shares)				7,419
Class of Warrant or Right, Outstanding (in shares)															38,000
The June 2019 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)														571,428	228,571			571,428
Class of Warrant or Right, Exercised During Period (in shares)														571,428	228,571
Class of Warrant or Right Call Feature Minimum Stock Price (in dollars per share)												$ 1					$ 1		$ 1
Class of Warrant or Right, Expired During Period (in shares)		571,428
Class of Warrant or Right, Outstanding (in shares)														0				0
Adjustments to Additional Paid in Capital, Warrant Issued														$ 497,000	$ 199,000
The June 2019 Warrants [Member] | China Kington [Member]
Exercise of Warrants, Commission, Percent														6.00%	6.00%			6.00%
Payments for Commission, Exercise of Warrants														$ 29,000	$ 12,000
The June 2019 Warrants [Member] | Private Placement [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)												1,371,427					1,371,427		1,371,427
Class of Warrant or Right, Issued During Period (in shares)												1,371,427
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 0.87					$ 0.87		$ 0.87
Warrants and Rights Outstanding, Term (Month)												1 year					1 year		1 year
The July 2011 Warrants [Member]
Warrants and Rights Outstanding															$ 0
Class of Warrant or Right, Expired During Period (in shares)				35,107														35,107
Class of Warrant or Right, Outstanding (in shares)															0
Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)							2,700,000
Proceeds from Issuance of Preferred Stock and Preference Stock							$ 2,700,000
Adjustments to Additional Paid in Capital, Beneficial Conversion Feature Upon Issuance of Stock					$ 800,000
Series A Preferred Stock [Member] | Private Placement [Member]
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs							$ 102,000

Note 12 - Stockholders' Equit_4

Note 12 - Stockholders' Equity - Outstanding Warrants (Details) shares in Thousands	6 Months Ended
	Jun. 30, 2020$ / sharesshares
Outstanding warrants (in shares) | shares	8,588
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.09
Warrants granted (in shares) | shares
Warrants granted, weighted average exercise price (in dollars per share) | $ / shares
Warrants exercised (in shares) | shares	(870)
Warrants exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 0.82
Warrants expired (in shares) | shares	(613)
Warrants expired, weighted average exercise price (in dollars per share) | $ / shares	$ 0.82
Outstanding warrants (in shares) | shares	7,105
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.15

Note 13 - Equity-based Compen_3

Note 13 - Equity-based Compensation (Details Textual) - USD ($) $ in Thousands	Apr. 01, 2020	Apr. 29, 2019	May 26, 2016	Jan. 31, 2017	Jan. 31, 2012	Jan. 31, 2011	Jan. 31, 2010	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Oct. 31, 2007
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value										$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)									83,000		83,000
Proceeds from Stock Options Exercised									$ 189		$ 189
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)										520,000
Share-based Payment Arrangement, Expense								$ 126	123	$ 183	237
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										$ 0
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)								520,000		125,000
Share-based Payment Arrangement, Expense								$ 128	116	$ 174	223
Nonemployees [Member]
Share-based Payment Arrangement, Expense								2	$ 7	9	$ 14
Share-based Payment Arrangement, Option [Member] | Mr. Liu [Member]
Share-based Payment Arrangement, Expense		$ 14
Share-based Payment Arrangement, Option [Member] | Mr. Yanbin Liu [Member]
Share-based Payment Arrangement, Expense		$ 7
Share-based Payment Arrangement, Option [Member] | Ms. Gail Maderis [Member]
Share-based Payment Arrangement, Expense	$ 36
Employee Stock Options and RSUs [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 743		$ 743
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)										2 years 116 days
Restricted Stock [Member]
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued (in shares)										0	0
Restricted Stock [Member] | Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)										160,000	0
Restricted Stock [Member] | Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)										0	0
The 2007 Omnibus Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)																	80,000
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Annual Increase in Shares Authorized (in shares)																40,000
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock															4.00%	4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)			1,124,826		40,000	37,427	37,207					139,449	82,461	32,646	59,157
Increase (Decrease) in Number of Shares Available for Grant (in shares)				610,774
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum										10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)										4 years
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										100.00%
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										110.00%
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
The 2017 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock								4.00%		4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)								2,318,486		2,318,486
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)								3,044,090		3,044,090
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum										10.00%
The 2017 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)										4 years
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										100.00%
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										110.00%
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										10 years
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)										5 years

Note 13 - Equity-based Compen_4

Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares
Outstanding awards (in shares)	2,183
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 4.03
Outstanding, weighted-average remaining contractual life (Year)	6 years 354 days	6 years 219 days
Outstanding, aggregate intrinsic value | $	$ 384	$ 43
Options granted (in shares)	520
Options granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.97
Options forfeited/cancelled (in shares)	(167)
Options forfeited/cancelled, weighted-average exercise price (in dollars per share) | $ / shares	$ 5.83
Outstanding awards (in shares)	2,692	2,183
Outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 3.10	$ 4.03
Vested and expected to vest (in shares)	2,573
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares	$ 3.20
Vested and expected to vest, weighted-average remaining contractual life (Year)	6 years 306 days
Vested and expected to vest, aggregate intrinsic value | $	$ 336
Vested (in shares)	1,848
Vested, weighted-average exercise price (in dollars per share) | $ / shares	$ 4.04
Vested, weighted-average remaining contractual life (Year)	5 years 310 days
Exercisable (in shares)	1,848
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares	$ 4.04
Exercisable, weighted-average remaining contractual life (Year)	5 years 310 days
Restricted Stock Units (RSUs) [Member]
Restricted stock units granted (in shares)	160
Restricted stock units vested (in shares)	(3)
Restricted stock units vested, weighted-average exercise price (in dollars per share) | $ / shares
Restricted stock units cancelled (in shares)	(1)

Note 13 - Equity-based Compen_5

Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Expected price volatility	159.81%	106.86%
Expected term (Year)	6 years 156 days	6 years 58 days
Risk-free interest rate	0.50%	2.08%
Dividend yield	0.00%	0.00%
Weighted-average fair value of options granted during the period (in dollars per share)	$ 0.93	$ 0.27

Note 13 - Equity-based Compen_6

Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Stock-based compensation expense	$ 126	$ 123	$ 183	$ 237
Research and Development Expense [Member]
Stock-based compensation expense	7	13	14	24
Selling and Marketing Expense [Member]
Stock-based compensation expense	11	27	20	46
General and Administrative Expense [Member]
Stock-based compensation expense	$ 108	$ 83	$ 149	$ 167

Note 14 - Revenue (Details Text

Note 14 - Revenue (Details Textual) - USD ($)	1 Months Ended				2 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2013	Oct. 31, 2012	Sep. 30, 2012	Jan. 31, 2012	Oct. 31, 2012	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2014	Dec. 31, 2019
Revenue from Contract with Customer, Including Assessed Tax						$ 3,984,000	$ 1,789,000	$ 5,876,000	$ 3,280,000
Partner Pharmacies [Member] | Revenue, Segment Benchmark [Member] | Customer Concentration Risk [Member]
Concentration Risk, Percentage						4.00%	25.00%	7.00%	25.00%
Reallocated from Deferred Revenue [Member]
Stockholders' Equity, Period Increase (Decrease), Total					$ 600,000
Avenova Product [Member]
Revenue from Contract with Customer, Including Assessed Tax						$ 1,140,000	$ 1,580,000	$ 2,686,000	$ 3,030,000
Avenova Direct [Member]
Revenue from Contract with Customer, Including Assessed Tax						600,000		1,400,000
KN95 Masks [Member]
Revenue from Contract with Customer, Including Assessed Tax						2,839,000		3,012,000
China Pioneer [Member]
Proceeds from Issuance or Sale of Equity, Total			$ 2,500,000
Unit Purchase Agreement Shares Per Unit (in shares)			1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)			1
Excess Fair Value Over Proceeds Received From Purchase					$ 1,000,000
China Pioneer [Member] | Tranche One [Member]
Purchase Agreement Units (in shares)			800,000
China Pioneer [Member] | Tranche Two [Member]
Purchase Agreement Units (in shares)		1,200,000
Purchase Agreement Unit Price Per Share (in dollars per share)		$ 1.25
Purchase Unit Agreement Total Units Fair Value		$ 3,500,000
China Pioneer [Member] | NeutroPhase [Member]
Proceeds from Collaborators	$ 312,500			$ 312,500						$ 625,000
Maximum Possible Sales Discounts			$ 500,000
Contract with Customer, Liability, Revenue Recognized						0	0	173,000	209,000
Phase One Health, LLC [Member]
Proceeds from Collaborators						115
China Pioneer and Principal Business Enterprise Inc. [Member] | Samples and Future Products [Member]
Contract with Customer, Liability, Revenue Recognized						5,000	0	5,000	41,000
McKesson Corporation [Member] | Avenova Product [Member]
Contract with Customer, Liability, Revenue Recognized						400,000	$ 1,300,000	900,000	$ 2,500,000
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]
Contract with Customer, Liability, Total						400,000		400,000
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]
Contract with Customer, Rebate Liability, Current						$ 100,000		$ 100,000			$ 400,000

Note 14 - Revenue - Changes in

Note 14 - Revenue - Changes in Assets and Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Contract Liabilities: Deferred Revenue, Balance at beginning of the period
Contract Liabilities: Deferred Revenue, additions	674
Contract Liabilities: Deferred Revenue, deductions	(559)
Contract Liabilities: Deferred Revenue, Balance at the end of the period	115
Contract Liabilities: Accrued Liabilities,Balance at beginning of the period	434
Contract Liabilities: Accrued Liabilities, additions	1,020
Contract Liabilities: Accrued Liabilities, deductions	(1,096)
Contract Liabilities: Accrued Liabilities, Balance at the end of the period	358
Contract Liabilities, Balance at beginning of the period	434
Contract Liabilities, additions	1,694
Contract Liabilities, deductions	(1,655)
Contract Liabilities, Balance at the end of the period	$ 473

Note 14 - Revenue - Total Reven

Note 14 - Revenue - Total Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total sales, net	$ 3,984	$ 1,789	$ 5,876	$ 3,280
Transferred over Time [Member]
Total sales, net			434	1,473
Transferred at Point in Time [Member]
Total sales, net			$ 5,442	$ 1,807

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
The 401(k) Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0	$ 0	$ 0

Note 16 - Related Party Trans_2

Note 16 - Related Party Transactions (Details Textual) - USD ($)	May 15, 2020	May 13, 2020	Aug. 08, 2019	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Accounts Receivable, Related Parties				$ 0					$ 0		$ 0
Accounts Payable, Related Parties				418,000			$ 0		418,000	$ 0
Related Party Transaction, Expenses from Transactions with Related Party				29,000			144,000
Stock Issued During Period, Shares, New Issues (in shares)			4,198,566			4,198,566
Proceeds from Issuance of Common Stock			$ 4,200,000						5,220,000	2,467,000
Pioneer Hong Kong [Member] | Promissory Note [Member]
Repayments of Long-term Debt, Total	$ 1,000,000
China Pioneer [Member] | Product [Member]
Revenue from Related Parties				0			209,000		173,000	209,000
Related Party Costs				0			176,000		90,000	176,000
China Pioneer [Member] | License and Collaboration Fees [Member]
Revenue from Related Parties				0			$ 0		0	41,000
China Kingston [Member]
Related Party Transaction, Expenses from Transactions with Related Party									$ 91,000	$ 214,000
China Kingston [Member] | Broker Fee for Issuance of Promissory Note [Member]
Related Party Transaction, Expenses from Transactions with Related Party				29,000	$ 12,000
China Kington [Member] | Broker Fee for Issuance of Promissory Note [Member]
Related Party Transaction, Expenses from Transactions with Related Party								$ 20,000
Director Bob Wu [Member] | Consulting Fee Pursuant to Consulting Agreement [Member]
Related Party Transaction, Expenses from Transactions with Related Party					$ 50,000			$ 50,000
TLF Bio Innovation [Member]
Related Party Transaction, Expenses from Transactions with Related Party				75,000
Stock Issued During Period, Shares, New Issues (in shares)		1,000
Proceeds from Issuance of Common Stock		$ 1,000
Chongqing Pioneer [Member] | Shipping and Customs Fees on Behalf Related Party [Member]
Related Party Transaction, Amounts of Transaction				$ 79,000

Note 18 - Paycheck Protection_2

Note 18 - Paycheck Protection Program (Details Textual) - USD ($) $ in Thousands	May 06, 2020	Jun. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Deferred Income, Paycheck Protection Plan		$ 432	$ 432	$ 0
Paycheck Protection Program CARES Act [Member]
Other Nonoperating Income		$ 469	$ 469
Paycheck Protection Program CARES Act [Member] | Wells Fargo Bank [Member]
Proceeds from Issuance of Long-term Debt, Total	$ 901

Note 19 - Subsequent Events (De

Note 19 - Subsequent Events (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Jul. 20, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019	Oct. 09, 2019	Aug. 31, 2019	Aug. 13, 2019	Aug. 08, 2019	Jul. 31, 2011
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.15		$ 1.09					$ 33.25
Proceeds from Warrant Exercises		$ 669	$ 46
Subsequent Event [Member]
Proceeds from Warrant Exercises	$ 6,400
The 2019 Domestic Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1.15	$ 1.15	$ 1.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						4,198,566		4,198,566
The 2019 Domestic Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.99
The 2019 Ladenburg Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1.25	$ 1.25	$ 1.25
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						167,942
The 2019 Ladenburg Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	0.99
New Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.65
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	6,898,566
Warrants and Rights Outstanding, Term (Month)	5 years 182 days
The 2019 Foreign Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)					$ 1.15	$ 1.15
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)					2,700,000	2,700,000		2,700,000
The 2019 Foreign Warrants [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.99